Clinical trials: Hepatic Malignancies
Biliary Tract Neoplasms, Pancreatic Neoplasm
Portal Vein Stenting for Malignant Obstruction: Feasibility, Safety, and Clinical Outcomes
Introduction: Pre-hepatic portal hypertension of malignant origin can lead to severe complications such as refractory ascites or gastrointestinal bleeding, significantly impairing patients' quality of life.
- Conditions
- Biliary Tract Neoplasms, Pancreatic Neoplasm, Portal Hypertension, Portal Vein Thrombosis
- Trial name
- NCT07252570
- Testing
- Transhepatic portal vein stent implantation
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Pancreatic Cancer
Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma
This study aims to evaluate the prognostic impact of the detection of circulating tumor DNA in peripheral venous blood, portal venous blood, collected intraoperatively, as well as its detection in peritoneal fluid.
- Trial name
- VEINOPAN (NCT06478056)
- Testing
- pancreatectomy
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Rouen
Hepatic Neoplasm
Scandinavian Cohort Study for Optimal Use of Portal Vein Embolization
Several aspects on the use of portal vein embolization (PVE) are poorly studied and todays recommendations are based on low-grade evidence.
- Trial name
- NCT04182386
- Testing
- Portal vein embolization
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Karolinska University Hospital
Hepatic Neoplasm Malignant
Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients
Primary Objective: To evaluate the efficacy of SECOX regimen by adding oxaliplatin plus capecitabine to sorafenib versus sorafenib alone as palliative treatment for unresectable HCC patients to prolong overall survival (OS) for…
- Trial name
- SECOX (NCT01245582)
- Testing
- oxaliplatin (SR96669), capecitabine, sorafenib
- Sponsor
- Sanofi
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT
This multicenter retrospective study evaluated consecutive patients with large HCC and PVTT who received lenvatinib plus DEB-TACE with/without FOLFOX-HAIC between July 2019 and June 2021.
- Trial name
- NCT06265883
- Testing
- Len+DEB-TACE+HAIC, Len+DEB-TACE
- Where
- China
- Volunteers
- 205 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Congenital Portosystemic Shunt, CPSS (Congenital Portosystemic Shunt)
International Registry of Congenital Portosystemic Shunt (IRCPSS)
Congenital Portosystemic Shunt (CPSS) is a rare condition important by the multiplicity and severity of associated complications.
- Trial name
- IRCPSS (NCT06041906)
- Testing
- Shunt Closure
- Where
- 26 sites in United States, Australia and 14 more
- Volunteers
- 500 people
- Sponsor
- Prof. Valérie Mc Lin
Advanced Cancers
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
The goal of this clinical research study is to find the highest tolerable dose of the combination of oxaliplatin and capecitabine with or without bevacizumab that can be given to patients with advanced cancer that has spread to…
- Trial name
- NCT01213238
- Testing
- Oxaliplatin, Capecitabine, Bevacizumab
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma, Neoplasm Metastasis
Hepatic Artery Infusion Pump for NPC Liver Metastases
A retrospective clinical trial to study the safety and effectiveness of hepatic arterial infusion (HAI) in treating patients who have nasopharyngeal carcinoma metastatic to the liver.
- Conditions
- Nasopharyngeal Carcinoma, Neoplasm Metastasis, Liver
- Trial name
- NCT03876574
- Testing
- DSA-guided implantation of hepatic artery infusion pump, Gemcitabine, Floxuridine
- Volunteers
- 16 people
- Sponsor
- Xiangya Hospital of Central South University
Colorectal Cancer, Metastatic Cancer
Cryosurgery in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
RATIONALE: Cryosurgery for liver metastases may have fewer side effects and improve recovery. PURPOSE: Phase II trial to study the effectiveness of cryosurgery for patients with unresectable liver metastases from colorectal…
- Trial name
- NCT00002997
- Testing
- cryosurgery
- Where
- 3 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Uveal Melanoma, Hepatic Metastases
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
Reports to date show limited efficacy of immunotherapy for uveal melanoma. Recent experimental and clinical evidence suggests synergy between radiation therapy and immunotherapy.
- Trial name
- NCT02913417
- Testing
- SIR-Spheres® Yttrium 90, ipilimumab, nivolumab
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- David Minor, MD
Advanced Solid Tumors
Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function
Panobinostat (LBH589) is a deacetylase inhibitor (DACi) which belongs to a structurally novel cinnamic hydroxamic acid class of compounds.
- Trial name
- NCT01007968
- Testing
- LBH589
- Where
- 6 sites in United States, Netherlands and 3 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
HER2-amplified Biliary Tract Cancers
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
This multicenter, open-label, single-arm trial will evaluate the anti-tumor activity of ZW25 (zanidatamab) monotherapy in subjects with human epidermal growth factor receptor 2 (HER2)-amplified, inoperable and advanced or…
- Trial name
- HERIZON-BTC-01 (NCT04466891)
- Testing
- ZW25 (Zanidatamab)
- Where
- 67 sites in United States, Canada and 7 more
- Volunteers
- 87 people
- Sponsor
- Jazz Pharmaceuticals
Colorectal Cancer Liver Metastases (CRLM), Small Future Liver Remnant (FLR)
The DRAGON 2 Trial
In the randomized controlled DRAGON 2 trial study subjects will be randomized between two arms, PVE alone (control group) and PVE/HVE (interventional group).
- Trial name
- DRAGON 2 (NCT05428735)
- Testing
- Embolization
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 348 people
- Sponsor
- Maastricht University
Hepatocellular Carcinoma, Hepatic Metastasis
Palliative Radiotherapy (RT) for Liver Metastases (Mets) and Hepatocellular Carcinoma (HCC)(COLD 4)
Palliative radiotherapy is radiation treatment given to help reduce pain or discomfort, or other symptoms related to cancer. This is used commonly for cancer that has spread to the bones and brain, and for many other primary…
- Trial name
- NCT00923897
- Testing
- Palliative RT
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Esophageal Cancer, Advanced Solid Tumor
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
To evaluate the pharmacokinetics and safety of Larotinib in subjects with mild and moderate hepatic function impairment and healthy subjects in a single-center, non-randomized, open, single-dose administration
- Trial name
- NCT05048368
- Testing
- Larotinib
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) participants with moderate and severe…
- Trial name
- NCT05660395
- Testing
- Loncastuximab Tesirine
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 5 people
- Sponsor
- ADC Therapeutics S.A.
Colon Cancer Liver Metastases, Liver Neoplasms
Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM)
Surgical resection has offered the best option for prolonged survival in patients with colorectal liver metastases. Limiting factor for major liver resections is the size of the future liver remnant (FLR).
- Conditions
- Colon Cancer Liver Metastases, Liver Neoplasms, Liver Diseases, Secondary Malignant Neoplasm of Liver
- Trial name
- ALPPSforCRLM (NCT02758977)
- Testing
- ALPPS, TWO STAGE HEPATECTOMY
- Where
- Switzerland
- Volunteers
- 214 people
- Sponsor
- University of Zurich
Colorectal Neoplasms, Neoplasms
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Background: Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors are often treated using a hepatic artery infusion (HAI) pump.
- Conditions
- Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma
- Trial name
- NCT07715903
- Testing
- Carfilzomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Colorectal Carcinoma
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Determine the safety of a combination of IFN, celecoxib, and rintatolimod for patients with recurrent colorectal cancer. This will also test whether the above combination can help the immune system to fight the tumors.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Trial name
- NCT01545141
- Testing
- Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Thyroid Pathology, Head and Neck Cancer (H&N)
FAPI PET Imaging - An Exploratory Study
This study is testing a new imaging tracer called [18F]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions…
- Conditions
- Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis
- Trial name
- FAPIPET (NCT07705074)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 5 sites in Switzerland
- Volunteers
- 770 people
- Sponsor
- Martin Huellner
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.